Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Standard Therapy in Moderate-to-Severe Pemphigus Vulgaris
NCT07769333Phase 1Not yet recruiting
- Sponsor
- Khyber Teaching Hospital
- Start
- Dec 2026
- Primary completion
- May 2027
01
Overview
Phase 1, open-label trial of rituximab in pemphigus vulgaris (PV) (2 arms), sponsored by Khyber Teaching Hospital. Primary endpoints: Pemphigus Disease Area Index at 6 months and Complete Clinical Remission Rate at 12 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT07769333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07769333.